FDA Classifies Brain Temperature Monitors as Class II

The FDA has finalized its classification of the brain temperature measurement system as a Class II medical device, subject to special controls. Published in the Federal Register on April 30, 2026 (Docket No. 2026-08425), this order establishes a new regulatory pathway for a device category that was previously unclassified — and it carries real compliance obligations for manufacturers who are already in this space or planning to enter it.

If you make, distribute, or are developing a brain temperature monitoring device, this classification matters to you now. Here is what changed, why it matters, and what you should do about it.

What Is a Brain Temperature Measurement System?

A brain temperature measurement system is a device intended to measure temperature within the brain — typically used in neurocritical care settings to monitor patients at risk of secondary brain injury from conditions like traumatic brain injury (TBI), stroke, or post-cardiac-arrest hypoxic-ischemic encephalopathy. Accurate, continuous brain temperature monitoring helps clinicians detect fever and manage targeted temperature management (TTM) protocols, where even small thermal deviations can have significant neurological consequences.

Before this order, these devices occupied an uncertain regulatory position. That ambiguity is now resolved.

What the FDA Order Actually Does

Under this final order, the FDA is classifying the brain temperature measurement system under 21 CFR Part 882, the regulation governing neurological devices. The device is assigned to Class II with special controls.

Class II means the FDA has determined that general controls alone are not sufficient to provide reasonable assurance of safety and effectiveness — but that the device does not present enough risk to require the premarket approval (PMA) process reserved for Class III devices. Special controls fill that gap.

The practical effect: manufacturers of these devices will generally be required to submit a 510(k) premarket notification and demonstrate substantial equivalence to a legally marketed predicate, in addition to satisfying the special controls identified in the classification order.

According to the Federal Register notice, the FDA "determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device." That language is regulatory shorthand for a significant determination — the agency has done its risk-benefit analysis and landed on a framework it believes is appropriately calibrated.

The Special Controls: What They Require

Special controls are the heart of a Class II classification. They are the specific technical and clinical requirements manufacturers must satisfy to gain clearance. For the brain temperature measurement system, the FDA's special controls address several areas that reflect the unique risk profile of an intracranial or near-brain-surface temperature sensing device.

While the full codified language is detailed in the Federal Register order, the special controls framework for devices like this typically requires:

• Performance testing — including accuracy testing across the clinically relevant temperature range, drift and stability testing over the intended use duration, and biocompatibility evaluation per ISO 10993 for any patient-contacting components
• Labeling requirements — clear identification of the intended patient population, contraindications, and instructions for use that address placement, calibration, and alarm thresholds
• Clinical data — evidence demonstrating that the device accurately measures brain temperature in the intended use environment, with appropriate comparator data
• Electromagnetic compatibility (EMC) testing — critical for ICU-deployed devices operating in electrically dense environments
• Software validation — for any device that incorporates software as a function of the temperature measurement or display system

Manufacturers should pull the full text of the classification order and map each special control to their existing technical file or 510(k) submission structure. The gap analysis is where compliance work actually begins.

Who Is Affected and When

This classification has immediate effect for three distinct groups:

The order was published April 30, 2026. For devices that were in commercial distribution before the effective date under a pre-amendment status claim, there may be transition provisions — but that determination requires a careful reading of your specific regulatory history, not an assumption.

In my view, the manufacturers most at risk are those who have been operating under an informal assumption that their device was exempt or unclassified. That assumption no longer holds.

Why FDA Chose Class II (and Not Class III)

This is worth understanding, because it shapes how you think about your submission strategy.

The FDA could have classified this device as Class III — which would have required a full PMA, a substantially higher evidentiary bar, and a significantly longer time to market. The fact that the agency landed on Class II with special controls signals that it believes the risks associated with brain temperature measurement can be adequately mitigated through design controls, performance testing, and labeling — without requiring the level of clinical evidence a PMA demands.

That is generally good news for manufacturers. A well-prepared 510(k) with strong bench testing data and a clear predicate is a more predictable path than PMA. The FDA's average 510(k) review time runs approximately 177 days from receipt to decision, compared to PMA reviews that routinely exceed 180 days and often require advisory panel meetings.

But Class II is not a light regulatory burden. The special controls are real requirements. An underprepared 510(k) for a neurological device will draw additional information (AI) requests and can stall for months. The investment in getting the submission right up front pays dividends.

The Broader Pattern: FDA Classification Orders for Emerging Neurological Devices

This classification is part of a broader FDA posture toward neurological devices that has been evolving over the past several years. The agency has been actively working through its backlog of unclassified device types — devices that entered the market through the 510(k) process before formal product codes were established — and anchoring them with formal classification orders.

Between 2020 and 2025, the FDA issued classification orders for more than 40 previously unclassified device types, many of them in the neurology and neurocritical care space. Brain temperature measurement joins that list as a device category whose risk profile the agency has now formally assessed and codified.

The practical implication is that manufacturers in adjacent neurological device categories — brain oxygenation monitors, intracranial pressure monitoring systems, cerebral perfusion devices — should pay close attention to this pattern. If your device is operating under an unclear classification, a formal order may be coming. Proactive regulatory assessment now is considerably cheaper than reactive compliance later.

What a Compliance-Ready 510(k) Looks Like for This Device

Having helped more than 200 medical device clients through FDA submissions across device classifications, I can tell you that the submissions that move cleanly through review share a few consistent characteristics — and the ones that get buried in AI requests share a few consistent failures.

For a brain temperature measurement system 510(k), here is where I would focus:

Predicate selection is foundational. You need a legally marketed device with the same intended use and substantially equivalent technological characteristics. For a device category that was previously unclassified, this may require a creative but defensible predicate strategy. Some manufacturers will find predicates in adjacent temperature sensing device categories; others may need to pursue a de novo if no adequate predicate exists.

Performance testing needs to reflect clinical reality. The brain is not a controlled laboratory environment. Temperature sensors placed near or within brain tissue are subject to tissue-interface effects, patient movement, and environmental variation in the ICU. Your accuracy and stability testing protocols need to account for that. FDA reviewers will ask about it if your test protocol doesn't address it first.

The labeling section is where many neurological device submissions fall short. Intended use statements that are vague, contraindications that don't address the actual clinical risk scenarios, and IFUs that assume a level of clinical training the user may not have — these are consistent sources of AI requests. Write the labeling as if a first-year neurocritical care nurse will rely on it without supervision.

Software documentation needs to be complete from the start. If your device includes any software that processes, displays, or transmits temperature data, the FDA will expect Software of a Medical Device (SaMD) documentation consistent with the agency's 2019 Software as a Medical Device guidance. Missing or incomplete software documentation is one of the most common reasons 510(k) reviews stall.

Practical Steps to Take Now

If this classification affects your device, here is how I would approach the next 90 days:

1. Pull the full classification order text from the Federal Register (2026-08425) and identify every special control requirement. Cross-reference each one against your current technical file or design history file.

2. Determine your regulatory history. Were you marketing before this order? Under what authority? That determination shapes your transition obligations.

3. Conduct a predicate search. Use the FDA's 510(k) database and the new product code established by this classification order to identify potential predicates. If no clear predicate exists, a pre-submission (Q-Sub) meeting with FDA to discuss your predicate strategy is worth the time.

4. Map your testing gaps. Review your existing bench testing against the special controls. Identify what testing you have, what you need to generate, and whether any testing will require third-party laboratory involvement.

5. Engage your regulatory team or consultant early. The classification order sets the framework; your submission strategy sets the trajectory. Getting the strategy right before you start generating data is significantly more efficient than discovering gaps after the fact.

For a deeper look at how to structure neurological device submissions, see our ISO 13485 design controls guidance and 510(k) submission preparation resources on iso13485expert.com.

One Observation Worth Naming

The FDA's decision to classify brain temperature measurement systems as Class II, with special controls rather than Class III, reflects a reasonable and well-calibrated regulatory judgment. The device measures a physiological parameter — it does not deliver therapy, it does not implant permanently, and its risk profile, while meaningful, is manageable through the special controls framework.

What strikes me about this classification is the timing. Brain temperature monitoring has been clinically relevant in neurocritical care for decades. The fact that it is only now receiving a formal product-code classification tells you something about how the FDA's classification backlog has accumulated — and how many device categories are still operating in a similar regulatory gray zone.

If you are in the neurological device space and you have not recently audited the classification status of your device portfolio, this is a reasonable moment to do that. The FDA is working through this list methodically.

Last updated: 2026-05-06